The estimated Net Worth of Rohan Palekar is at least $5.61 Million dollars as of 1 April 2024. Mr. Palekar owns over 52,718 units of 89bio Inc stock worth over $3,723,877 and over the last 5 years he sold ETNB stock worth over $863,326. In addition, he makes $1,022,610 as Chief Executive Officer and Director at 89bio Inc.
Rohan has made over 8 trades of the 89bio Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 52,718 units of ETNB stock worth $575,153 on 1 April 2024.
The largest trade he's ever made was exercising 100,000 units of 89bio Inc stock on 8 September 2022 worth over $193,000. On average, Rohan trades about 9,322 units every 37 days since 2020. As of 1 April 2024 he still owns at least 459,171 units of 89bio Inc stock.
You can see the complete history of Mr. Palekar stock trades at the bottom of the page.
Rohan Palekar serves as Chief Executive Officer, Director of the Company. Mr. Palekar served as the president and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a specialty pharmaceutical company, from December 2015 to July 2017, where he led the company following its acquisition by Otsuka Pharmaceutical Co., Ltd. in 2015. Mr. Palekar also served as Executive Vice President and Chief Operating Officer of Avanir in 2015 and as Senior Vice President and Chief Commercial Officer of Avanir from March 2012 to March 2015. Prior to Avanir, Mr. Palekar served as Chief Commercial Officer for Medivation, Inc., a biopharmaceutical company, from 2008 to 2011, where he was responsible for all commercial activities, chemistry, manufacturing and controls, medical affairs and public relations functions. Prior to Medivation, Mr. Palekar spent over 16 years at Johnson & Johnson, a diversified healthcare company, in various senior commercial and strategic management roles.
As the Chief Executive Officer and Director of 89bio Inc, the total compensation of Rohan Palekar at 89bio Inc is $1,022,610. There are no executives at 89bio Inc getting paid more.
Rohan Palekar is 54, he's been the Chief Executive Officer and Director of 89bio Inc since 2018. There are 7 older and 8 younger executives at 89bio Inc. The oldest executive at 89bio Inc is Michael Hayden, 68, who is the Independent Director.
Rohan's mailing address filed with the SEC is C/O 89BIO, INC., 142 SANSOME STREET, 2ND FLOOR, SAN FRANCISCO, CA, 94104.
Over the last 5 years, insiders at 89bio Inc have traded over $17,267,666 worth of 89bio Inc stock and bought 14,519,952 units worth $208,678,684 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Ra ..., and Advisors Llc Orbi Med Capit.... On average, 89bio Inc executives and independent directors trade stock every 28 days with the average trade being worth of $2,197,340. The most recent stock trade was executed by Rohan Palekar on 1 April 2024, trading 52,718 units of ETNB stock currently worth $575,153.
89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.
89bio Inc executives and other stock owners filed with the SEC include: